Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
DEFYMED
🇫🇷
France
Country
🇫🇷
France
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes
Not Applicable
Recruiting
Conditions
Type 1 Diabetes Mellitus With Hypoglycemia
Type 1 Diabetes
Interventions
Device: ExOlin®
Drug: Insulin aspart
Subscribe
First Posted Date
2022-02-03
Last Posted Date
2022-07-27
Lead Sponsor
Defymed
Target Recruit Count
8
Registration Number
NCT05221359
Locations
🇫🇷
Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Subscribe
Prev
1
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy